| |
Individuals with SCI |
Control group |
ANOVA interactiona |
Main group effect or between-
group
differenceb |
Main task effect or between- task differencec |
| Task #1 |
Task #2 |
Task #1 |
Task #2 |
|
Task #1 |
Task #2 |
SCI |
CTL |
| MDIST-RD (mm) |
1.80 ± 1.00 |
3.12 ± 2.14 |
1.24 ± 1.14 |
1.65 ± 1.27 |
|
# |
## |
| MDIST-AP (mm) |
1.12 ± 0.59 |
2.33 ± 1.67 |
1.07 ± 1.09 |
1.35 ± 1.25 |
|
|
|
## |
| MDIST-ML (mm) |
1.18 ± 0.92 |
1.69 ± 1.35 |
0.45 ± 0.36 |
0.70 ± 0.35 |
|
## |
# |
| RDIST-RD (mm) |
2.10 ± 1.13 |
3.55 ± 2.40 |
1.52 ± 1.46 |
1.88 ± 1.48 |
|
# |
## |
| RDIST-AP (mm) |
1.40 ± 0.72 |
2.84 ± 2.02 |
1.38 ± 1.43 |
1.63 ± 1.47 |
|
|
|
## |
| RDIST-ML (mm) |
1.45 ± 1.07 |
2.02 ± 1.49 |
0.56 ± 0.44 |
0.86 ± 0.43 |
|
## |
# |
| TOTEX-RD (mm) |
120.67 ± 46.54 |
248.38 ± 96.36 |
147.08 ± 70.67 |
180.33 ± 64.71 |
## |
|
** |
*** |
|
| TOTEX-AP (mm) |
80.36 ± 25.69 |
174.22 ±78.05 |
116.52 ± 56.42 |
126.16 ± 41.09 |
### |
|
* |
*** |
|
| TOTEX-ML (mm) |
72.00 ± 37.19 |
139.68 ± 60.54 |
66.42 ± 36.26 |
102.30 ± 43.29 |
|
|
|
### |
| RANGE-RD (mm) |
8.89 ± 4.62 |
14.70 ± 8.04 |
7.34 ± 6.78 |
8.18 ± 5.67 |
# |
|
* |
* |
|
| RANGE-AP (mm) |
6.89 ± 3.63 |
13.02 ± 7.36 |
7.10 ± 6.75 |
7.89 ± 5.69 |
# |
|
|
* |
|
| RANGE-ML (mm) |
6.53 ± 4.33 |
9.43 ± 5.37 |
3.26 ± 2.27 |
4.90 ± 3.41 |
|
## |
## |
| MVELO-RD (mm/s) |
4.02 ± 1.55 |
8.29 ± 3.21 |
4.90 ± 2.36 |
6.01 ± 2.16 |
## |
|
** |
*** |
|
| MVELO-AP (mm/s) |
2.68 ± 0.86 |
5.82 ± 2.60 |
3.88 ± 1.88 |
4.21 ± 1.37 |
### |
|
* |
*** |
|
| MVELO-ML (mm/s) |
2.40 ± 1.24 |
4.66 ± 2.02 |
2.21 ± 1.21 |
3.41 ± 1.44 |
|
|
|
### |
| AREA-CC (mm2) |
49.77 ± 49.15 |
154.21 ± 223.42 |
42.32 ± 92.04 |
49.37 ± 106.80 |
|
|
|
|
|
| AREA-CE (mm2) |
29.86 ± 25.09 |
103.83 ± 143.20 |
19.64 ± 35.26 |
28.74±43.52 |
|
|
|
# |
| AREA-SW (mm2/s) |
2.56 ± 2.10 |
7.89 ± 5.52 |
2.18 ± 3.02 |
3.59 ± 5.08 |
# |
|
** |
** |
|
| MFREQ-RD (Hz) |
0.43 ± 0.20 |
0.53 ± 0.20 |
0.82 ± 0.42 |
0.68 ± 0.22 |
|
## |
|
|
| MFREQ-AP (Hz) |
0.55 ± 0.34 |
0.56 ± 0.22 |
0.90 ± 0.52 |
0.71 ± 0.29 |
|
# |
|
|
| MFREQ-ML (Hz) |
0.46 ± 0.24 |
0.66 ± 0.30 |
1.07 ± 0.39 |
0.91 ± 0.27 |
# |
*** |
|
|
|
| FD-RD |
1.39 ± 0.09 |
1.45 ± 0.09 |
1.50 ± 0.12 |
1.51 ± 0.08 |
|
## |
|
|
| FD-CC |
1.48 ± 0.11 |
1.54 ± 0.12 |
1.64 ± 0.16 |
1.62 ± 0.10 |
|
## |
|
|
| FD-CE |
1.53 ± 0.11 |
1.58 ± 0.11 |
1.71 ± 0.15 |
1.65 ± 0.08 |
# |
*** |
|
|
|
| T POWER-RD |
13.71 ± 6.99 |
13.96 ± 5.09 |
18.37 ± 6.28 |
14.76 ± 3.51 |
|
|
|
|
|
| T POWER–AP |
31.97 ± 21.45 |
33.56 ± 19.65 |
45.41 ± 25.63 |
37.25 ± 19.41 |
|
|
|
|
|
| TPOWER-ML |
35.21 ± 20.56 |
40.18 ± 21.74 |
58.52 ± 21.04 |
48.64 ± 18.30 |
|
## |
|
|
| 50%-RD (Hz) |
0.33 ± 0.08 |
0.56 ± 0.25 |
0.81 ± 0.46 |
0.61 ± 0.24 |
## |
*** |
|
** |
|
| 50%-AP (Hz) |
0.41 ± 0.21 |
0.55±0.29 |
0.69 ± 0.41 |
0.49 ± 0.24 |
# |
* |
|
|
|
| 50%-ML (Hz) |
0.42 ± 0.29 |
0.51 ± 0.23 |
0.78 ± 0.19 |
0.70 ± 0.27 |
|
### |
|
|
| 95%-RD (Hz) |
1.98 ± 0.55 |
2.28 ± 0.65 |
2.88 ± 0.87 |
2.88 ± 0.42 |
|
### |
|
|
| 95%-AP (Hz) |
2.02 ± 0.67 |
2.02 ± 0.60 |
2.57 ± 0.79 |
2.58 ± 0.35 |
|
## |
|
|
| 95%-ML (Hz) |
1.54 ± 0.51 |
2.05 ± 0.38 |
2.68 ± 0.45 |
2.53 ± 0.37 |
### |
*** |
** |
*** |
|
| CFREQ-RD (Hz) |
0.89 ± 0.21 |
1.08 ± 0.28 |
1.40 ± 0.47 |
1.33 ± 0.24 |
|
### |
|
|
| CFREQ-AP (Hz) |
0.97±0.29 |
0.99 ± 0.30 |
1.27 ± 0.42 |
1.16 ± 0.22 |
|
### |
|
|
| CFREQ-ML (Hz) |
0.80 ± 0.25 |
1.01 ± 0.23 |
1.34 ± 0.28 |
1.28 ± 0.20 |
# |
*** |
*** |
** |
|
| FREQD-RD |
0.72 ± 0.04 |
0.67 ± 0.05 |
0.66 ± 0.07 |
0.68 ± 0.05 |
# |
** |
|
* |
|
| FREQD-AP |
0.70 ± 0.05 |
0.66 ± 0.06 |
0.67 ± 0.05 |
0.69 ± 0.06 |
# |
* |
|
* |
|
| FREQD-ML |
0.66 ± 0.09 |
0.66 ± 0.06 |
0.62 ± 0.04 |
0.62 ± 0.06 |
|
### |
|
|
aANOVA interaction results. b Main group effect or t-tests between groups when ANOVA interaction was significant in the supported (Task #1) or unsupported sitting
position (Task #2). c Main task effect or t-tests between tasks within each group when ANOVA interaction was significant. For interaction and main effect, #=p<0.05; ##=p ≤ 0.01; ###=p ≤ 0.001. For t-tests with Bonferroni adjustments, *=p<0.025;**=p≤0.01;***p≤0.001. SCI: individuals with SCI; CTL: control group. |
